USFetus Randomized Clinical Trial: Sequential vs. Standard Laser Treatment of Twin-twin Transfusion Syndrome
USFetus Randomized Clinical Trial: Sequential vs. Standard Laser Treatment of Twin-twin Transfusion Syndrome
The investigators hypothesize that treatment of twin-twin transfusion syndrome (TTTS) using sequential laser photocoagulation of communicating vessels (SQLPCV) over the predominant method, selective laser photocoagulation of communicating vessels (SLPCV), may provide vascular stability to the donor fetus. The primary objective is to evaluate the perinatal outcome, specifically, donor intrauterine survival of TTTS managed by SQLPCV vs. SLPCV in a prospective, randomized trial.
Inclusion Criteria:
Gestational age: 16 weeks, 0 days to 26 weeks, 0 days.
Confirmed TTTS patients, who by definition meet the following sonographic criteria:
Patients choosing laser therapy that have undergone prior therapeutic amniocentesis may be included.
Patients with an anterior placenta may be included.
Triplet gestations with two or three fetuses sharing the same placenta may be included.
Patients must be able to give written informed consent.
Exclusion Criteria: